BeBetter Med, Inc.SSE: 688759

Announcement on Expected Loss in Performance for 2025

Jan 24, 2026 · Issued by BeBetter Med, Inc. via Shanghai Stock Exchange

Filed with SSE · Jan 24, 2026

On 6ix: 6ix.com/news/announcement-on-expected-loss-in-performance-for-2025-172

Announcement on Expected Loss in Performance for 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

BeBetter Med, Inc. on 6ix

Earlier from BeBetter Med

Announcement on Abnormal Fluctuations in Stock TradingJan 8
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025Nov 29, 2025
Announcement on Changing Registered Capital and Business Type, Amending the Articles of Association and Handling Industrial and Commercial Change RegistrationNov 13, 2025

Later from BeBetter Med

Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business LicenseJan 30
BEBETTER MED INC." -- Announcement on Voluntary Disclosure of Clinical Trial Applications for BEBT-701 Approved by China NMPAFeb 4
Announcement on Opening Special Settlement Account for Cash Management of Raised FundsFeb 12
Announcement on Preliminary Earnings Estimate for 2025Feb 28
Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for Iprinosine Hydrochloride for Injection (BEBT-908) Combined with CHOP in the Treatment of Newly Diagnosed Peripheral T-Cell LymphomaMar 14

All BeBetter Med news releases

Follow BeBetter Med into a list and get an email when it puts out news.

Follow BeBetter Med